2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon

The piece recommends Vertex Pharmaceuticals and DexCom as long-horizon healthcare picks: Vertex, which dominates cystic fibrosis treatments with patents into the late 2030s, delivered Q3 2025 revenue of $3.08 billion (+11% YoY), net income of $1.1 billion and $12 billion in cash, and is de-risking growth through a deep pipeline and new franchises (Casgevy gene‑editing with CRISPR Therapeutics, Journavx non‑opioid pain therapy, Alfytrek, plus investigational assets like Zimislecel, inaxaplin and povetacicept) that target markets potentially larger than CF; DexCom remains the leading continuous‑glucose‑monitoring provider with substantial underpenetrated demand (fewer than 1% of Type 1 diabetics use CGMs), product cadence (G7/G8) and an OTC launch (Stelo) to broaden its TAM, and reported Q3 revenue growth of 22% with GAAP operating income of $242.5 million (20.1% of revenue, +480 bps YoY).

Analysis

The article highlights Vertex Pharmaceuticals (VRTX) and DexCom (DXCM) as multidecade healthcare investment candidates, citing Vertex's Q3 2025 results—$3.08 billion in revenue (up 11% year‑over‑year), $1.1 billion in net income and $12 billion in cash, and DexCom's Q3 revenue growth of 22% with U.S. up 21% and international up 22%. Vertex's CF franchise benefits from patents into the late 2030s, providing a stable cash base to fund R&D and M&A, while DexCom leverages market leadership in continuous glucose monitoring to expand addressable market share.

Vertex's growth thesis centers on expanding beyond cystic fibrosis through recently commercialized and investigational assets: Casgevy (gene editing with CRISPR Therapeutics), Journavx (non‑opioid acute pain), Alfytrek (CF triple therapy), plus Zimislecel, inaxaplin and povetacicept targeting larger disease populations. DexCom's catalysts are product cadence (G7, forthcoming G8), the OTC Stelo launch to reach non‑insulin users and prediabetics, and improving profitability (GAAP operating income $242.5 million, 20.1% of revenue, +480 bps YoY).

The significance for investors is clear: both companies show durable near‑term fundamentals and structural growth vectors, but upside depends on successful clinical/regulatory execution, commercial uptake and continued reimbursement expansion. Key risks include binary pipeline outcomes, market volatility noted for DXCM, and eventual patent cliffs for Vertex; these factors argue for active milestone monitoring and disciplined position sizing.

Key Decisions for Investors

• Consider establishing a core, long‑horizon position in VRTX to capture CF cash flow and pipeline optionality while sizing the stake to reflect pipeline binary risk and the company’s $12 billion cash cushion
• Accumulate DXCM on meaningful dips to play secular CGM adoption, OTC expansion with Stelo and product upgrades (G7/G8), acknowledging the stock’s recent volatility and prioritizing purchases on pullbacks
• Monitor near‑term, trade‑moving catalysts—Vertex clinical/regulatory readouts (Zimislecel, inaxaplin, povetacicept) and commercial uptake of Casgevy/Journavx, plus DexCom’s G8 launch, Stelo rollout and reimbursement trends—and adjust exposure around those outcomes
• Maintain disciplined position sizing and consider hedges against binary trial outcomes and patent‑expiry timing despite solid reported fundamentals (VRTX Q3 revenue $3.08B; DXCM 22% revenue growth and 20.1% operating margin)